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Epilepsy Therapy Goes Viral
Epilepsy Gene Therapy Using an Engineered Potassium Channel
Snowball A, Chabrol E, Wykes RC, Shekh-Ahmad T, Cornford JH, Lieb A, Hughes MP, Massaro G, Rahim AA, Hashemi KS,
Kullmann DM, Walker MC, Schorge S. J Neurosci. 2019;39(16):3159-3169.
Refractory focal epilepsy is a devastating disease for which there is frequently no effective treatment. Gene therapy represents
a promising alternative, but treating epilepsy in this way involves irreversible changes to brain tissue, so vector design must be
carefully optimized to guarantee safety without compromising efficacy. We set out to develop an epilepsy gene therapy vector
optimized for clinical translation. The gene encoding the voltage-gated potassium channel Kv1.1, KCNA1, was codon opti-
mized for human expression and mutated to accelerate the recovery of the channels from inactivation. For improved safety,
this engineered potassium channel (EKC) gene was packaged into a nonintegrating lentiviral vector under the control of a cell
type-specific CAMK2A promoter. In a blinded, randomized, placebo-controlled preclinical trial, the EKC lentivector robustly
reduced seizure frequency in a male rat model of focal neocortical epilepsy characterized by discrete spontaneous seizures.
When packaged into an adeno-associated viral vector (AAV2/9), the EKC gene was also effective at suppressing seizures in a
male rat model of temporal lobe epilepsy. This demonstration of efficacy in a clinically relevant setting, combined with the
improved safety conferred by cell type–specific expression and integration-deficient delivery, identifies EKC gene therapy as
being ready for clinical translation in the treatment of refractory focal epilepsy.
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Commentary
Gene therapy has been envisioned since the 1970s but has faced
a number of difficult obstacles, both in the laboratory and the
clinic. Following early success of a clinical trial for adenosine
deaminase - severe combined immunodeficiency (ADA-SCID)
in 1990, subsequent clinical failures quickly led to dismissal of
gene therapy as nothing more than an experimental technique.
However, over the last 15 years, there have been dramatic
improvements in human genetics, genome editing strategies,
methods for gene delivery, and disease modeling, all of which
has made this innovative therapeutic strategy move at an
increasingly rapid pace toward every day clinical practice.1
This has led to a renewed interest in the promise of gene ther-
apy for a wide range of human diseases, highlighted by a recent
Food and Drug Administration approval for the treatment of
spinal muscular atrophy.2 However, despite many convincing
advances in the field, antiepileptic gene therapy remains at a
preclinical proof-of-principle stage. There are a number of
important challenges that must be overcome in order to move
this exciting technology to the clinic for epilepsy, such as
choice of gene or pathway to target, viral packaging,
off-target effects, successful delivery into the human brain,
safety, and even the inherent heterogeneous etiology of epilepsy
itself. With potentially more than 100 genes reported to cause
epilepsy,3 many of which are expressed throughout the brain
and/or body, it is difficult to envision applying the traditional
concept of gene therapy (ie, to fix a defective gene or pathway)
for each individual monogenetic disorder. In contrast,
approaches that target more downstream pathways to manipulate
the expression of genes that control neuronal or circuit excitabil-
ity in affected brain areas may have broader application.4
Snowball and colleagues built upon their prior work5,6
developing a viral vector–mediated gene therapy to alter neu-
ronal and circuit excitability in focal neocortical epilepsy. This
approach involves overexpression of the human KCNA1 gene,
which encodes the voltage-gated potassium channel Kv1.1, in
epileptogenic foci. Here, the authors engineered and optimized
the viral construct used in earlier studies with the goal of gen-
erating an effective gene therapy that might be ready for clin-
ical translation. To do this, they first replicated and extended
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their prior work by demonstrating a dramatic suppression of
spontaneous seizures following the delivery of a CMV-driven
KCNA1 lentivirus directly into the seizure focus in visual cor-
tex of a tetanus toxin model. This construct was then modified
in 3 main ways: (1) the non-cell-type-specific CMV promotor
was exchanged for a CAMK2A promotor to drive Kv1.1 expres-
sion in excitatory projection neurons, (2) the Kv1.1 gene was
modified to reduce its inactivation, and (3) the resulting plas-
mid was packaged into a nonintegrating lentiviral vector to
reduce the potential risk of mutagenesis. This new, refined
construct had even more powerful therapeutic effects on sei-
zures in the tetanus toxin model of focal epilepsy, presumably
due to increased specificity for targeting excitatory neurons,
and it was also effective in a kainic acid model of temporal
lobe epilepsy, when packaged into an AAV vector and injected
bilaterally into hippocampus.
Neocortical epilepsy is often drug-resistant, and surgery to
remove the epileptogenic zone is not always feasible or effec-
tive. As such, development of a spatially restricted, cell-type-
specific gene therapy that selectively modifies the activity of
neurons at the seizure focus could be an important advance. If
successful, this strategy might also spare unaffected brain
regions or minimize the types of side effects seen in current
pharmacological approaches. Although the results reported by
Snowball and colleagues are promising, additional hurdles
remain before eventual translation to the clinic. For example,
the authors only evaluated the effect of this gene therapy on
seizures, and it is not yet known how overexpression of Kv1.1
in CAMK2A neurons might alter visual cortex function. In
thinking about moving from rodent to human, large animal
studies may be necessary for determining how to precisely
deliver the vector to epileptic foci of a gyrated neocortex.
Ultimately, for clinical trials to succeed, one must decide
who will be an appropriate candidate for therapy. A patient
with drug-resistant epilepsy and a well-defined focal lesion in
eloquent cortex has been considered to be an ideal candidate.
The most prevalent pathologic substrate of epilepsy surgery is
focal cortical dysplasia, which has been identified in both mag-
netic resonance imaging positive and negative cases.7
However, if a gene therapy is effective and safe, and can be
broadly applied to many forms of the disease as indicated in the
current study, it may be advantageous to develop this technol-
ogy for a wider range of patients regardless of whether or not a
focal epileptogenic zone is present. It is possible that such a
therapy could be useful in acquired epilepsy, such as following
a traumatic brain injury or stroke, as well as in genetic epilep-
sies. As such, this study by Snowball and colleagues provides
an important step closer to achieving successful gene therapy
for epilepsy.
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